NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis → $5,000 Gold? (From Stansberry Research) (Ad) Free ORGS Stock Alerts $0.53 +0.00 (+0.91%) (As of 11:48 AM ET) Add Compare Share Share Today's Range$0.50▼$0.5750-Day Range$0.39▼$0.9052-Week Range$0.25▼$1.50Volume36,865 shsAverage Volume205,222 shsMarket Capitalization$18.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Orgenesis alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Orgenesis Stock (NASDAQ:ORGS)Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Read More ORGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORGS Stock News HeadlinesApril 25, 2024 | americanbankingnews.comOrgenesis (NASDAQ:ORGS) Shares Down 3.3% April 17, 2024 | investing.comOrgenesis secures $2.3 million investment and strategic partnershipMay 2, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …April 17, 2024 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 15, 2024 | globenewswire.comOrgenesis Provides Year End Business UpdateApril 11, 2024 | investing.comGermfree partners with Orgenesis to enhance CGT productionApril 10, 2024 | globenewswire.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityMarch 18, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMay 2, 2024 | Weiss Ratings (Ad)Protect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …March 13, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesMarch 4, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementFebruary 29, 2024 | globenewswire.comOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingFebruary 23, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS)February 22, 2024 | morningstar.comOrgenesis Inc ORGSJanuary 31, 2024 | msn.comEXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To ClinicJanuary 31, 2024 | finance.yahoo.comOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicJanuary 8, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo FinanceNovember 22, 2023 | finance.yahoo.comAnalysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven SoonNovember 15, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNovember 13, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the Third Quarter of 2023November 8, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNovember 5, 2023 | forbes.com6 Secrets Of Organizations That Successfully Adapt To ChangeNovember 2, 2023 | finance.yahoo.comOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingOctober 31, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Proposed Underwritten Public OfferingSee More Headlines Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today5/01/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees146Year Founded2008Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-1,010.50% Pretax Margin-12,159.43% Return on Equity-924.61% Return on Assets-460.85% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$530,000.00 Price / Sales34.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-0.80Miscellaneous Outstanding Shares34,355,000Free Float31,902,000Market Cap$18.06 million OptionableOptionable Beta1.07 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Vered Caplan M.Sc. (Age 55)Chairperson of the Board, CEO & President Comp: $341.38kProf. Sarah Ferber Ph.D. (Age 70)Founder & Chief Scientific Officer Comp: $268.32kMr. Victor Miller (Age 54)CFO, Secretary & Treasurer Pierre LammeretzInterim Chief Operating OfficerDr. Shimon Hassin Ph.D.Chief Technology OfficerMr. Evan FishmanChief Financial Officer of Orgenesis BiotechMr. Joseph CarpinelliChief Financial Officer of OctomeraMore ExecutivesKey CompetitorsTalpheraNASDAQ:TLPHAvalo TherapeuticsNASDAQ:AVTXVincerx PharmaNASDAQ:VINCChembio DiagnosticsNASDAQ:CEMIMinerva NeurosciencesNASDAQ:NERVView All CompetitorsInsidersJacob SafierBought 10,100 shares on 2/1/2024Total: $3,333.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/30/2024Total: $8,250.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/25/2024Total: $8,000.00 ($0.32/share)Jacob SafierBought 10,000 shares on 1/22/2024Total: $2,900.00 ($0.29/share)Jacob SafierBought 10,000 shares on 1/18/2024Total: $3,300.00 ($0.33/share)View All Insider Transactions ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed in 2024? Orgenesis' stock was trading at $0.5007 at the beginning of the year. Since then, ORGS shares have increased by 1.0% and is now trading at $0.5055. View the best growth stocks for 2024 here. Are investors shorting Orgenesis? Orgenesis saw a increase in short interest in April. As of April 15th, there was short interest totaling 402,500 shares, an increase of 34.3% from the March 31st total of 299,700 shares. Based on an average daily volume of 235,300 shares, the days-to-cover ratio is currently 1.7 days. View Orgenesis' Short Interest. When is Orgenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ORGS earnings forecast. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.21. The firm earned $6.98 million during the quarter. Orgenesis had a negative net margin of 1,010.50% and a negative trailing twelve-month return on equity of 924.61%. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Orgenesis have any subsidiaries? The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.Read More This page (NASDAQ:ORGS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTrackerTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
